DC
Therapeutic Areas
IGM Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Imvotamab (IGM-2323) | Relapsed/Refractory Non-Hodgkin's Lymphoma, DLBCL, Follicular Lymphoma | Phase 2 |
| Aplitabart (IGM-8444) | Solid Tumors (Colorectal, Ovarian, etc.) | Phase 1/2 |
| IGM-7354 | Autoimmune & Inflammatory Diseases (via IL-6R) | Phase 1 |
| IGM-2644 | Multiple Myeloma | Preclinical |
| IGM-2537 | IgE-Mediated Allergies | Preclinical |
Leadership Team at IGM Biosciences
FS
Fred Schwarzer
Chief Executive Officer
BK
Bruce Keyt, Ph.D.
Chief Scientific Officer & Head of Research
JM
Joel Martin, Ph.D.
Senior Vice President, Manufacturing & Process Sciences
BS
Bryan Sakamoto, M.D., Ph.D.
Senior Vice President, Clinical Development
BC
Bruce Carter, Ph.D.
Board Member
JB
James Breitmeyer, M.D., Ph.D.
Board Member